Key2Brain AB

Key2Brain AB is a dynamic biotechnology company focused on pioneering next-generation brain-targeting therapies. Leveraging its innovative blood-brain barrier-crossing technology, Key2Brain AB enables efficient brain uptake and broad distribution of therapeutics, enhancing the potential for treating various neurological conditions.

Based in Stockholm, Sweden, Key2Brain AB integrates its proprietary technology with a wide range of therapeutic molecules. This approach facilitates the development of both internal pipeline projects and collaborative partnerships. The company is committed to advancing healthcare solutions through cutting-edge research and development in the biotechnology sector.

The team at Key2Brain AB leverages extensive industry experience in biologics and brain-targeting drugs to accelerate the translation from discovery to clinical applications. With a focus on innovation and strategic partnerships, Key2Brain AB is poised to make significant contributions to the field of brain therapeutics. We invite the management of Key2Brain AB to create a customized and exclusive company showcase and product listing on our platform.